Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages

Journal of Pathology

Volumn 227, Issue 1, 2012, Pages 17-28

  Linde, Nina ^a   Lederle, Wiltrud ^b   Depner, Sofia ^a   Van Rooijen, Nico ^c   Gutschalk, Claudia M ^a   Mueller, Margareta M ^a,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d FURTWANGEN UNIVERSITY   (Germany)

Author keywords

IL 10; IL 4; Inflammation; Macrophages; SCC; Skin carcinogenesis; Tumour microenvironment; VEGF

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SKIN CARCINOGENESIS; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; BONE MARROW CELLS; CELL LINE, TRANSFORMED; CELL MOVEMENT; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-10; INTERLEUKIN-4; KERATINOCYTES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS; TRANSFECTION; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859643154     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3989     Document Type: Article

References (46)

1. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-1081.
2. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001; 193: F23-26. (Pubitemid 32524459)
3. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78. (Pubitemid 38082155)
4. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-265. (Pubitemid 34189413)
5. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555. (Pubitemid 35223554)
6. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759. (Pubitemid 41400849)
7. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006; 124: 823-835. (Pubitemid 43261455)
8. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69(suppl 3): 4-10. (Pubitemid 41680947)
9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611. (Pubitemid 39099316)
10. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005; 69(suppl 3): 11-16. (Pubitemid 41680948)
11. Zittermann SI, Issekutz AC. Endothelial growth factors VEGF and bFGF differentially enhance monocyte and neutrophil recruitment to inflammation. J Leukoc Biol 2006; 80: 247-257. (Pubitemid 44835498)
12. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-3343. (Pubitemid 26115364)
13. Hiratsuka S, Minowa O, Kuno J, et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95: 9349-9354. (Pubitemid 28506234)
14. Hiratsuka S, Maru Y, Okada A, et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001; 61: 1207-1213. (Pubitemid 32174444)
15. Kerber M, Reiss Y, Wickersheim A, et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 2008; 68: 7342-7351.
16. Lederle W, Linde N, Heusel J, et al. Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. Am J Pathol 2010; 176: 981-994.
17. Boukamp P, Petrussevska RT, Breitkreutz D, et al. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106: 761-771. (Pubitemid 18089976)
18. Stacey A, Doyle A. Routine testing of cell cultures and their products for mycoplasma contamination. Methods Mol Biol 1997; 75: 305-311.
19. Angstmann M, Brinkmann I, Bieback K, et al. Monitoring human mesenchymal stromal cell differentiation by electrochemical impedance sensing. Cytotherapy 2011; 13: 1074-1089.
20. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174: 83-93.
21. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
22. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22: 231-237.
23. Obermueller E, Vosseler S, Fusenig NE, et al. Cooperative autocrine and paracrine functions of granulocyte colonystimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res 2004; 64: 7801-7812. (Pubitemid 39446913)
24. Simonetti O, Lucarini G, Goteri G, et al. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol 2006; 19: 751-760. (Pubitemid 46145039)
25. Canavese M, Altruda F, Ruzicka T, et al. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis - a possible target for novel therapies? J Dermatol Sci 2010; 58: 171-176.
26. Schonthaler HB, Huggenberger R, Wculek SK, et al. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA 2009; 106: 21264-21269.
27. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009; 136: 585-595.
28. Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004; 10: 1095-1103. (Pubitemid 39424871)
29. Averboukh F, Ziv Y, Kariv Y, et al. Colorectal carcinoma in inflammatory bowel disease-A comparison between Crohn's and ulcerative colitis. Colorectal Dis 2011; 13: 1230-1235.
30. Chen YJ, Wu CY, Chen TJ, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol 2011; 65: 84-91.
31. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 2008; 180: 2011-2017.
32. Xiong M, Elson G, Legarda D, et al. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol 1998; 153: 587-598. (Pubitemid 28373669)
33. Harmey JH, Dimitriadis E, Kay E, et al. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor β1. Ann Surg Oncol 1998; 5: 271-278. (Pubitemid 28249320)
34. Lin EY, Li JF, Bricard G, et al. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol 2007; 1: 288-302. (Pubitemid 350181649)
35. Shurin MR, Lu L, Kalinski P, et al. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 1999; 21: 339-359. (Pubitemid 30011443)
36. Itakura E, Huang RR, Wen DR, et al. IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol 2011; 24: 801-809.
37. Kim J, Modlin RL, Moy RL, et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 1995; 155: 2240-2247.
38. Li Z, Jiang J, Wang Z, et al. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 2008; 68: 8687-8694.
39. + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
40. Howard M, Farrar J, Hilfiker M, et al. Identification of a T cell-derived β cell growth factor distinct from interleukin 2. J Exp Med 1982; 155: 914-923. (Pubitemid 12187863)
41. Min B, Prout M, Hu-Li J, et al. Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite. J Exp Med 2004; 200: 507-517. (Pubitemid 39121907)
42. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004; 25: 235-241. (Pubitemid 38501669)
43. Pouliot P, Turmel V, Gelinas E, et al. Interleukin-4 production by human alveolar macrophages. Clin Exp Allergy 2005; 35: 804-810. (Pubitemid 40961355)
44. Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998; 111: 1-6. (Pubitemid 28309201)
45. Asadullah K, Sterry W, Stephanek K, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998; 101: 783-794. (Pubitemid 28096075)
46. Zhu K, Ye J, Wu M, et al. Expression of Th1 and Th2 cytokine associated transcription factors, Tβ and GATA-3, in peripheral blood mononuclear cells and skin lesions of patients with psoriasis vulgaris. Arch Dermatol Res 2010; 302: 517-523.